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ABSTRACT
A CROSS-SECTIONAL STUDY OF PHTHALATE EXPOSURE AND
INFLAMMATION BIOMARKER LEVELS AMONG POSTMENOPAUSAL WOMEN
MAY 2020
AVERY TRIM, B.S., UNIVERSITY OF MASSACHUSETTS AMHERST
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed By: Dr. Katherine Reeves
Phthalates are industrial chemicals added to plastics found in products such as
children’s toys, cosmetics, and household items, and some laboratory studies suggest
phthalates may increase levels of inflammation. Chronic inflammation is associated with
many chronic health conditions, such as diabetes and rheumatoid arthritis. Although
research is limited, recent studies suggest a strong positive relationship between monobutyl phthalate (MBP), mono-isobutyl phthalate (MiBP), and monocarboxynonyl
phthalate (MCNP) and c-reactive protein (CRP), as well as monoethyl phthalate (MEP)
and mono-3-carboxypropyl phthalate (MCPP) and interleukin-6 (IL-6). Additionally, this
relationship has not been examined among postmenopausal women, a population that is
at higher risk of developing chronic health conditions. Our aim was to examine the
association between urinary phthalate biomarkers and inflammation biomarkers among
postmenopausal women using baseline data from a subset of participants of the Women’s
Health Initiative (WHI) (n=443). Phthalate exposure was assessed using phthalate
biomarkers (i.e. phthalate metabolites or their molar sum) from urine samples collected at
WHI clinical centers from 1993-1998. We measured 13 phthalate metabolites: MEP,
MBP, mono-hydroxybutyl phthalate (MHBP), MiBP, mono-hydroxyisobutyl phthalate
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(MHiBP), monobenzyl phthalate (MBzP), MCPP, mono (2-ethylhexyl) phthalate
(MEHP), mono (2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), mono (2-ethyl-5oxohexyl) phthalate (MEOHP), mono (2-ethyl-5-carboxypentyl) phthalate (MECPP),
mono-carboxyoctyl phthalate (MCOP), and MCNP. Serum and plasma inflammatory
biomarker levels (i.e. CRP, IL-6) were measured in separate WHI ancillary studies, using
blood samples collected at baseline. We used multivariable linear regression to analyze
associations between each phthalate biomarker and inflammation biomarker, adjusting
for important covariates. Phthalate biomarkers MCNP (Model 1: b = 0.523; Model 2: b =
0.362) and MCOP (Model 1: b = 0.384; Model 2: b = 0.240) were positively associated
with CRP. Additionally, MCNP (Model 1: b = 0.369; Model 2: b = 0.181) was positively
associated with IL-6. Statistically significant associations were not observed among the
remaining phthalate biomarkers. Our findings suggest that certain phthalates may be
related to increasing levels of inflammation.
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CHAPTER I
INTRODUCTION
Accumulating scientific evidence, especially in recent years, indicates a
potentially harmful relationship between phthalates and inflammation. Phthalates are
man-made chemicals added to plastics, and can be found in many everyday household,
personal care, medical, and child products.1 Detectable concentrations have been
observed among the majority of the U.S. population in varying amounts.2 Inflammation is
a response to the presence of unknown substances within the body and is a natural
defense mechanism that typically occurs in acute phases.3 However, chronic
inflammation, which often goes unresolved,3 is associated with rheumatoid arthritis4,
Alzheimer’s disease,5 diabetes,5,6 cancer,5–7 cardiovascular disease6,8 and osteoporosis9,
which are prevalent among postmenopausal women.
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) is
suggested as a potential mechanism behind the association between phthalates and
inflammation. It is hypothesized that phthalate exposure leads to the activation of NF-kB,
which signals the production of pro-inflammatory cytokines, such as interleukin-6 (IL6).10 NF-kB is also shown to stimulate production of c-reactive protein (CRP), however
this process is suggested to occur through IL-6 and interleukin 1 beta (IL-1b).11
Animal and cellular studies indicate that phthalate exposure can increase the
production of pro-inflammatory cytokines, although this positive relationship is typically
observed in higher phthalate metabolite concentrations.10,12–17 Prior epidemiological
studies also indicate positive associations between phthalate metabolites MBP, MiBP,
and MCNP and CRP, as well as MEP and MCPP and IL-6.18–20 Directionality among
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other phthalate metabolites is inconsistent and may be due to insufficient power from
small sample sizes, or the use of a single phthalate urinary sample.18–21
Prior research studies have not examined the relationship between phthalate
metabolite concentrations and inflammation biomarker levels among postmenopausal
women only. We investigated the associations between 13 phthalates metabolite and 2
inflammation biomarkers using 1993-1998 baseline data from a subset of Women’s
Health Initiative (WHI) participants.
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CHAPTER II
SUBJECTS AND METHODS

A. Study population
WHI is a large-scale national study evaluating potential strategies to prevent and
minimize causes of morbidity and mortality among postmenopausal women.22 WHI
conducted three clinical trials as well as a separate observational study from 1993-1998,
enrolling a total of 161,808 postmenopausal women from 50-79 years old.23,24 Written
informed consent was provided upon enrollment.24 In addition, WHI conducted a bone
density substudy at three clinical sites, which included 11,020 participants from any of
the clinical trials or the observational study. Our nested case-control study selected breast
cancer cases and 2:1 matched controls from among WHI bone density substudy
participants.23,25 A number of ancillary studies also occurred throughout the WHI study
and measured inflammatory biomarkers on selected participants. Our cross-sectional
study included selected participants from the nested-case control study with inflammatory
biomarker values measured at baseline from overlapping ancillary studies (n=443).
Participants were excluded if they 1) were missing baseline covariate information, and 2)
had results measured using unreliable assays (i.e. those with high CV). Figure 1 shows
the study population ascertainment for this analysis.

B. Phthalate exposure assessment
Phthalate exposure was assessed using biomarkers (i.e. urinary phthalate metabolites).
First morning void urinary samples were conducted by participants at home and
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refrigerated until their baseline visit at a WHI clinical center. During this visit samples
were acquired and frozen by trained personnel until they were ready for shipment to
McKesson Bioservices, where they were stored at -80°C. Participant samples used for the
WHI nested-case control study were taken from McKesson Bioservices and sent to the
CDC for processing and analysis. Urine samples were analyzed for 13 phthalate
metabolites (MEP, MBP, MHBP, MiBP, MHiBP, MBzP, MCPP, MEHP, MEHHP,
MEOHP, MECPP, MCOP, and MCNP) using enzymatic deconjugation of the
glucuronidated analytes, followed by assessment of exposure levels using on-line solid
phase extraction and high performance liquid chromatography-electrospray ionizationtandem mass spectrometry. Each phthalate metabolite (or their molar sum) were
considered as continuous variables in the analyses.
Phthalate exposure was assessed using an objective measure (i.e. urine sample). In
addition, laboratory workers were not privy to any information that could identify
participants based on their urinary sample, such as disease status. Coefficient of variation
(CV), which uses blinded duplicate samples to examine potential differences in lab
values, was used on 10% of phthalate metabolite samples to assess validity. CVs were
5.4% for MBP, 6.1% for MBzP, 4.7% for MCNP, 6.3% for MCOP, 5.8% for MCPP,
4.3% for MECPP, 5.4% for MEHHP, 19.5% for MEHP, 6.0% for MEOHP, 3.1% for
MEP, 9.0% for MHBP, 21.9% for MHiBP, and 10.3% for MiBP.23 Phthalate metabolite
concentrations below the limit of detection (LOD) were given a value equal to LOD /
Ö2.23 Five phthalate metabolites had samples whose concentrations were below the LOD
(MBP = 0.07%, MEHP = 0.63%, MHBP = 0.43%, MHiBP = 1.56%, MiBP = 0.46%.23
All samples from the eight other phthalate metabolites were above the LOD.
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C. Inflammation biomarker assessment
Blood samples were collected at WHI clinical centers during the first screening
visit, prior to which participants were required to fast for at least 12 hours. Participants
were also asked to refrain from smoking, taking aspirin or nonsteroidal anti-inflammatory
drugs (NSAIDs), or partaking in strenuous physical activity prior to their visit. To
separate plasma (ethylenediaminetetraacetic acid (EDTA) and citrate) and serum from the
blood, samples were left to clot at 4°C for approximately one hour and then centrifuged
for 10 minutes. Separated serum and plasma were then placed into multiple smaller vials
and frozen at -70°C for 2 hours until they were ready to be shipped to McKesson
Bioservices for permanent storage at -80°C. Samples were then shipped from McKesson
Bioservices to a laboratory for analysis. Among the 22 ancillary studies included in our
final sample, inflammation biomarker levels were measured at approximately 10 different
laboratories using around 6 different assay methods (Immulite Immunoasasy Analyzer,
Enzyme Linked Immunosorbent Assay (ELISA), Quantikine High Sensitivity
Immunoassay, Luminex Multiplex Cytokine Assay, Roche Modular P Chemistry
Analyzer, Behring Nephelometer II Analyzer). Inflammation biomarkers were measured
as continuous variables in our analyses.
An average CV percentage was calculated based on groupings by biomarker,
sample type, testing method, and lab.26 Average CVs ranged from 1.9% to 9.2% among
CRP values,27 and 4% to 42% among IL-6 values.27 The correlation coefficient, which
measures the degree of association between blinded duplicate sample pairs, was
calculated and averaged based on groupings by biomarker, sample type, testing method,
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and lab.26 Average correlation coefficients ranged from 0.9-1.0 among CRP values and
0.75-1.0 among IL-6 values.27

D. Consolidation of inflammation biomarker results
Some participants had multiple CRP and/or IL-6 results from various WHI ancillary
studies. Among participants with more than one specimen type (i.e. citrate, serum,
EDTA) per inflammation biomarker, a single result was selected based on the frequency
of specimen types within the total sample. Random sampling was used in order to select
one result per biomarker and participant. Additionally, to harmonize inflammation
biomarker results across ancillary studies, predicted values of each inflammatory
biomarker were calculated from linear regression models using strong predictors
including age, smoking status, BMI, use of anti-inflammatory medication 48 hours prior
to blood draw, ancillary study ID (i.e. assay method and lab), and storage time (i.e. the
time between blood draw and assay). Predicted CRP levels equal to zero were given a
value of 0.025 (ng/mL or pg in order to allow for log transformation of values.

E. Covariate assessment
Sociodemographic and behavioral characteristics, as well as medical history were
ascertained from a self-report questionnaire completed at first screening visit. Physical
measurements (ex. Height, blood pressure) were taken at first screening visit. Current
medication information was determined by collection of participant medications at first
screening visit and later recording prescription information. We included age,18,21,28
creatinine,18 race/ethnicity,18,20 socioeconomic status,21 smoking status,21 alcohol intake,21
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and BMI18–21 as covariates based on prior epidemiological studies. Total physical activity
was also included as a covariate, as prior literature indicates confounding between
phthalate exposure and inflammation.23,29

F. Statistical analysis
Phthalate biomarkers (i.e. individual metabolites or their molar sums) and
inflammation biomarkers were natural log transformed for data to follow a normal
distribution. Demographic and behavioral characteristics of the study population were
summarized by inflammation biomarker and compared to distributions in the nested casecontrol study. T-tests or chi-square tests were used to examine potential differences in
characteristics between participants sample sizes for each inflammation biomarker and
the nested case-control study. Distributions (i.e. mean, standard deviation, range) of
phthalate biomarker (creatinine-standardized) and inflammation biomarker levels were
calculated. Pearson’s correlations were calculated to assess the level of dependence of
each phthalate biomarker and inflammation biomarker.
Two multivariable linear regression models were used to examine the relationship
between each phthalate biomarker and inflammation biomarker. Covariates which
produced at least a 10% change in inflammation biomarker level estimates were included
in both models. Model 1 was adjusted for age, creatinine, socioeconomic status, alcohol
intake, and smoking status as covariates. Model 2 was adjusted for covariates included
Model 1 as well as BMI. Among most phthalate biomarkers, race/ethnicity and total
physical activity had little impact on the estimated association with inflammation
biomarkers (<10% change) in both models, and therefore were not included as covariates.
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Our analyses included 443 participants (CRP, n=414; IL-6, n=177) who had complete
data on covariates, exposure, and outcome. As a sensitivity analysis, we repeated our
multivariable linear regression analyses using participants who were not identified as
current NSAID users based on medication data collection at baseline. For all of our
analyses, a p-value < 0.05 was considered statistically significant.
Power calculations were based on a Type III F test within a multiple linear
regression model. Among participants with CRP values (n=414), we had >80% power to
explain 10-20% of variability (i.e. standard error) in values with 95% confidence, based
on the inclusion of 6 predictors and use of continuous phthalate metabolites. Using the
same criteria, we had >80% power among participants with IL-6 values (n=177).
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CHAPTER III
RESULTS

Table 2 describes the distribution of sociodemographic and behavioral
characteristics of the study participants in this cross-sectional study by inflammation
biomarker, in comparison to the distribution within the nested case-control study.
Compared to participants within the nested case-control study, participants with CRP
values were more likely to be non-white, non-drinkers, have a higher annual income and
lower socioeconomic status. Similarly, participants with IL-6 values were more likely to
be older, non-white, past-smokers, and consume less than 1 drink per week.
Table 3 describes the distribution of creatinine-standardized phthalate biomarker
concentrations and inflammation biomarker levels among all study participants. MBzP,
MCPP, MCOP and MCNP concentrations have similar values ranging from 0.007 µg/g to
2.558 µg/g. SDEHP, SDBP, and SDiBP concentrations have similar values ranging from
0.00003 µg/g to 0.083 µg/g. MEP concentrations range from 0.088 µg/g to 130 µg/g,
with an average value of 3.8 µg/g. The distribution of CRP levels ranges from 0.025
mg/L to 16.4 mg/L, with a mean of 14.9 mg/L and a standard deviation of 3.0 mg/L. IL-6
levels range from 0.029 pg/mL to 11.2 pg/mL, with a mean of 2.9 pg/mL and a standard
deviation of 2.0 pg/mL.
Table 4 describes the relationship between each creatinine-standardized phthalate
biomarker and inflammation biomarker using Pearson’s correlation. Overall, results
indicate a weak, non-significant correlation between each phthalate biomarker and
inflammation biomarker. However, we observed statistically significant, positive
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correlation between MCNP and IL-6 (r = 0.20, p = 0.01).
Multivariable linear regression models assessing the relationship between each
creatinine-standardized phthalate biomarker and inflammation biomarker are shown in
Tables 5 and 6. Coefficients represent the change in inflammatory biomarker per 10-unit
change in the phthalate metabolite on the natural scale. Model 1 is adjusted for age,
creatinine, alcohol intake, socioeconomic status, and smoking status. Model 2 is adjusted
for covariates in Model 1 as well as BMI. We observed statistically significant, positive
associations between MCNP and CRP in both models: Model 1 (b = 0.523; p = 0.0002),
Model 2 (b = 0.362; p = 0.004). Similarly, we found a statistically significant positive
association between MCNP and IL-6 in Model 1 (b = 0.369, p = 0.01), but not in Model
2. We also observed a statistically significant positive association between MCOP and
CRP in Model 1 (b = 0.384, p = 0.01) and a borderline significant positive association in
Model 2 (b = 0.240, p = 0.05). Similar results were observed when restricting these
analyses to participants not currently using NSAIDs (Tables 7 and 8).
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CHAPTER IV
DISCUSSION

Overall, we did not observe strong, statistically significant associations between
urinary phthalate biomarkers and CRP or IL-6 in our sample of postmenopausal women
from WHI. We found a significant positive association between MCNP and CRP when
including and excluding BMI as a covariate, with comparable findings between MCOP
and CRP. A similar trend is observed among participants not currently using NSAIDs,
indicating that NSAID use does not affect the relationship between phthalates and
inflammation. Ferguson et al. observed positive associations for MCNP, and positive and
negative associations for MCOP.18,19 We also found a statistically significant, positive
association between MCNP and IL-6 when excluding BMI as a covariate, which was
attenuated and not statistically significant when including BMI as a covariate. Ferguson
et al. 2014 found an increase in IL-6 levels in association with an interquartile range
increase in MCNP (%Δ = 16.8, 95% CI: 2.69, 32.9, p=0.02) while adjusting for BMI.
Our results suggest a positive association between MCNP and inflammation, as
this relationship was observed among both inflammation biomarkers (CRP and IL-6).
Although a statistically significant relationship was observed between MCOP and CRP,
this was not observed with IL-6, which is potentially the result of reduced sample size
and statistical power. Our results also show an attenuation in strength of the association
between phthalate biomarkers and inflammation biomarker levels in models including
BMI as a covariate, compared to models excluding BMI as a covariate. However, this
trend is not consistent across all phthalate metabolites. A potential explanation for the
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conflicting findings is the varying sources of phthalate exposure. Diet is a common
source of phthalate exposure among the majority of individuals.1 DiNP, which
metabolizes into MCOP can be found in food packaging,30 which often contain unhealthy
food items. Although information is not readily available, as of March 2020 past federal
regulations from the U.S Food & Drug Administration cite DiDP (i.e. MCNP) as a
substance used in food packaging.31 Furthermore, obesity is an established risk factor for
inflammation.6 As our sample population has an average BMI of 28 kg/m2 and a standard
deviation of roughly 6 kg/m2, indicating an overweight population, it is possible that the
attenuation in strength of association among some phthalates is the result of correctly
adjusting for confounding due to BMI. It is also a possibility that the relationship
between some phthalates and inflammation occurs indirectly through BMI. In this case,
linear regression models excluding BMI as a covariate more accurately reflect the true
association as compared to models including BMI as a covariate. The increased in
strength of association among certain phthalate biomarkers may be the result of
originating from an exposure source unrelated to BMI, such as indoor air or dust.1 This
could produce an overestimation of the association between phthalate exposure and
inflammation, as BMI is adjusted for unnecessarily. Our findings also suggest that
NSAID does not confound the relationship between phthalate exposure and
inflammation, as we observed similar associations among our restricted sample as
compared to our full sample.
A potential explanation for differences in findings across studies is the sample
population. A total of 5 prior epidemiological studies examined the relationship between
individual urinary phthalate metabolites and inflammation biomarkers. Sample
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populations include pregnant women and men and women of varying ages. Our study is
the first to examine the relationship between phthalate exposure and inflammation
biomarker levels among postmenopausal women only. It possible that certain populations
are impacted differently by inflammation, resulting in conflicting results across studies.
We excluded participants with missing exposure, outcome and covariates as well as
participants with inflammatory biomarker values obtained from unreliable assays (i.e.
those with high CV). The reduced sample size and lowered statistical power may have
contributed to differences between our findings compared to those from prior studies.
We observed null finding across all other phthalate metabolites, which differs
from prior epidemiological studies. A potential explanation for these null associations
could be differences in sample size and phthalate exposure assessment. Our study uses a
single urine sample to assess phthalate exposure in comparison to prior studies which use
up to 4 samples in a repeated cross-sectional study to measure change in phthalate
exposure over time. Phthalates quickly pass through the body and reduce to half their
original amount anywhere from 3 to 18 hours following exposure.32 As a result, a single
urine sample may not accurately reflect participants long-term exposure. This can also
create high within-person variation as phthalate metabolites concentrations can change
daily, leading to nondifferential misclassification among participants in our sample. As a
result, our observed association may be attenuated. Our sample sizes for CRP (n=414)
and IL-6 (n=177) are generally smaller compared to the sample sizes of prior studies. The
use of a single measurement as well as a small sample size increases the variability of
values and decreases the power, therefore reducing the ability to observe an association.
Our study is limited by the reliance on inflammatory biomarker levels that were
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combined from multiple WHI ancillary studies. Inflammatory biomarker levels varied by
specimen type, lab, assay method, and storage time, leading to differences in
measurement among our sample. Additionally, as inflammation biomarker levels were
selected based on availability from other studies, it is possible that by design, our sample
population is different (i.e. sicker, older) from the WHI study population. To minimize
potential measurement error, we used strong predictors of inflammation (i.e. age,
smoking status, BMI, use of anti-inflammatory medication 48 hours prior to blood draw,
study ID, and storage time) to estimate CRP and IL-6 values and standardize our results.
Results from our prediction model were in line with our expectations regarding
directionality (Table 1). However, we did not observe a statistically significant
relationship between predictors age and anti-inflammatory medication use and CRP
levels. We also did not observe a statistically significant relationship between predictors
age, smoking status, and anti-inflammatory medication use and IL-6 levels. As a result, it
is likely that some measurement error remains among our predicted CRP and IL-6 values.
To understand the level of bias that may have occurred through sample selection, we
compared the distribution of characteristics within our sample sizes for CRP (n=414) and
IL-6 (n=177) values to participants within the nested case-control study (n=1,257).
Although our samples differed by age, race/ethnicity, and SES index, the remaining
characteristics were not statistically significantly different from the nested case-control
sample.
There are several strengths to our cross-sectional study. First, this is the first study
to assess this association among postmenopausal women only. As this population is at
higher risk for developing inflammation-related chronic conditions (diabetes, rheumatoid
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arthritis, etc.), our findings could provide insight into the mechanism between phthalate
exposure and inflammation and could lead to improvements in disease prevention.
Second, although residual confounding is a potential concern in any study, we were able
to adjust for a large number of confounders in our analyses. As a result, we were able to
assess the potential impact of certain covariates on the relationship between urinary
phthalate biomarkers and inflammation biomarker levels. Third, we expect our results to
be generalizable to all postmenopausal women. Although the biological mechanism
between phthalate exposure and inflammation is not established, we do not expect that
mechanisms linking phthalate exposure to inflammation would vary by age,
race/ethnicity, or geographic location.
In conclusion, our study indicates an overall positive association between MCNP
and inflammation biomarkers CRP and IL-6. Although the relationship between MCNP
and IL-6 is borderline significant when including BMI as a confounder (p=0.05), it is
possible that BMI is instead an intermediary step between phthalate exposure and
inflammation. Further research should examine this relationship as it relates to BMI.
Additionally, future studies should aim to use a larger sample size and include additional
inflammation biomarkers (ex. TNF-a and IL-8).
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APPENDIX
SUPPLEMENTAL TABLES

Table 1. Beta coefficients and 95% confidence intervals for predictors of
inflammation and CRP and IL-6 levels

Age
Smoking status
Never smoked
Past smoker
Current smoker
BMI

CRP
Beta (95% CI)

p-value

0.02 (-0.05, 0.09)

0.56

Reference
2.25 (1.32, 3.19)
2.62 (0.76, 4.47)
0.45 (0.37, 0.53)

IL-6
Beta (95% CI)
0.002 (-0.07,
0.08)

p-value
0.95

-Reference
-b
<0.0001 0.44 (-0.49, 1.37)
0.93
b
0.005
0.21 (-1.93, 2.35)
0.19
b
<0.0001 0.15 (0.07, 0.23) 0.0003b

Anti-inflammatory
medication usea
No
Yes
a

Reference
-0.81 (-1.74,
0.11)

-0.08

Reference
-0.53 (-1.43,
0.37)

anti-inflammatory medication use in the last 48-hours prior to blood draw
p<0.05

b
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-0.25

Clinical Trials and Observational Study
n = 161,808

Bone Density Substudy
n = 11,020

Nested Case-Control Study
n = 1,257

Excluded (n=814)
• Missing CRP or IL-6 results
or results measured using
unreliable assays (n=798)
• Missing covariate information
(n=16)

Final Sample
n = 443

Figure 1. Study population ascertainment for the analysis of phthalate exposure and
inflammation biomarker levels in postmenopausal women
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CRP
N=266

Both
N=148

IL-6
N=29

Figure 2. Venn diagram of inflammation
biomarker results among participants
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Table 2. Distribution of sociodemographic and behavioral characteristics in the Women's
Health Initiative Study (WHI); 1993-1998

Age, years; Mean(SD)
Race/ethnicity; N(%)

CRP
sample
(n=414)

p-valuea

IL-6
sample
(n=177)

pvaluea

Nested case
control
(n=1,257)

63.1(7.0)

0.10
<0.0001b

64.0(6.5)

0.01b
0.01b

62.9(6.9)

White 247(59.7)
Non-white 167(40.3)
Education level; N(%)
Less than high school degree 121(29.5)
Post high school/some college 155(37.8)
College degree or higher 134(32.7)
Income level, yearly; N(%)
<35,000 214(54.6)
>=35,000 178(45.4)
SES index - inflation
70.4(10.5)
adjusted; Mean(SD)
Alcohol intake; N(%)
0 drinks per week
<1 drink per week
1-6 drinks per week
7+ drinks per week
Smoking status; N(%)
Never smoked
Past smoker
Current smoker
Body mass index, kg/m2;
Mean(SD)

133(75.1)
44(24.9)
0.47

1,045(83.1)
212(16.9)
1.00

48(27.8)
63(36.4)
62(35.8)
0.06

<0.0001b

0.39
88(52.7)
79(47.3)
72.5(10.0)

0.05
164(39.6)
141(34.1)
76(18.4)
33(8.0)

345(27.6)
456(36.5)
450(36.0)

0.46
0.61

60(33.9)
68(38.4)
35(19.8)
14(7.9)
0.63

241(58.2)
144(34.8)
29(7.0)
28.7(6.0)

0.06

585(49.1)
606(50.9)
73.1(8.7)

412(33.0)
431(34.5)
288(23.1)
117(9.4)
0.35

91(51.4)
76(42.9)
10(5.7)
28.2(5.6)

0.84

698(56.4)
461(37.3)
78(6.3)
28.1(5.8)

Physical activity level, MET
11.5(13.5)
0.52
12.1(13.3)
0.96
12.0(14.4)
hrs/week; Mean(SD)
Current NSAID use; N(%)
0.82
0.35
Yes 258(62.3)
105(59.3)
791(62.9)
No 156(37.7)
72(40.7)
466(37.1)
Abbreviations: NSAID, nonsteroidal anti-inflammatory drug; SES, socioeconomic; MET,
metabolic equivalent
a
p-values are for the comparison of CRP and IL-6 samples to the nested case-control sample
b
p<0.05
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Table 3. Distribution of creatinine-standardized phthalate metabolite
concentrations and inflammation biomarker levels in the Women's Health
Initiative (WHI) Study (n=443); 1993-1998
Phthalate
metabolites

Mean

SD

Min

25th
percentile

75th
percentile

Max

DEHP, umol/ga

0.0033

0.0050

0.0002

0.0016

0.0038

0.0831

DBP, umol/gb

0.0025

0.0029

0.0001

0.0010

0.0031

0.0359

0.0003
3.758
0.232
0.061
0.084
0.059
4.885
2.941

0.0004 0.00003
12.566 0.088
0.240
0.013
0.087
0.007
0.185
0.009
0.136
0.007
2.995
0.025
2.016
0.029

0.0001
0.544
0.099
0.028
0.032
0.023
2.836
1.650

0.0003
2.588
0.270
0.062
0.077
0.056
6.652
3.354

0.0046
130.046
2.149
1.152
2.558
2.372
16.415
11.227

c

DiBP, umol/g
MEP, ug/g
MBzP, ug/g
MCPP, ug/g
MCOP, ug/g
MCNP, ug/g
CRP (mg/L)d
IL-6 (pg/mL)e
a

sum of MEHP, MEHHP, MEOHP, and MECPP
sum of MBP and MHBP
c
sum of MiBP and MHiBP
d
n=414
b

e

n=177
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Table 4. Pearson correlation table for creatininestandardized phthalate metabolite concentrations
and inflammation biomarker levels in the Women's
Health Initiative (WHI) Study; 1993-1998
CRP
(n=414)
r
p
DEHPb

0.020

0.69

c

IL-6
(n=177)
r

p

0.031

0.68

DBP
-0.037
0.46
0.070
0.93
DiBPd
0.009
0.86
0.019
0.81
MEP
0.008
0.88
-0.017
0.83
MBzP
0.023
0.64
-0.088
0.24
MCPP
0.015
0.76
-0.028
0.72
MCOP
0.039
0.43
0.082
0.28
MCNP
0.080
0.12
0.202
0.007e
a
phthalate metabolite concentrations and
inflammation biomarker levels were logtransformed
b
sum of MEHP, MEHHP, MEOHP, and MECPP
c
sum of MBP and MHBP
d
sum of MiBP and MHiBP
e
p<0.05
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Table 5. Multiple linear regression and 95% confidence intervals for phthalate metabolite
concentrations and CRP levels (n=414)a
Model 1b
Beta (95% CI)

p-value

d

Model 2c
Beta (95% CI)

p-value

DEHP
0.248 (-0.061, 0.557)
0.11
0.103 (-0.142, 0.348)
0.41
e
DBP
-0.009 (-0.275, 0.256)
0.95
-0.071 (-0.280, 0.139)
0.51
f
DiBP
0.103 (-0.173, 0.380)
0.46
0.002 (-0.217, 0.221)
0.98
MEP
0.040 (-0.164, 0.243)
0.70
0.010 (-0.151, 0.170)
0.91
MBzP
0.110 (-0.164, 0.384)
0.43
-0.079 (-0.297, 0.139)
0.48
MCPP
0.218 (-0.099, 0.534)
0.18
0.136 (-0.115, 0.386)
0.29
g
MCOP
0.384 (0.076, 0.692)
0.01
0.240 (-0.004, 0.485)
0.05
MCNP
0.523 (0.276, 0.890)
0.0002g
0.362 (0.116, 0.607)
0.004g
a
phthalate metabolite concentrations and inflammation biomarker levels were logtransformed. coefficients shown are based on a 10-unit change on the natural scale
b
adjusted for age, creatinine, alcohol intake, socioeconomic status, and smoking status
c

adjusted for model 1 + BMI
d
sum of MEHP, MEHHP, MEOHP, and MECPP
e
sum of MBP and MHBP
f
sum of MiBP and MHiBP
g
p<0.05
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Table 6. Multiple linear regression and 95% confidence intervals for phthalate metabolite
concentrations and IL-6 levels (n=177)a
Model 1b
Beta (95% CI)

p-value

d

Model 2c
Beta (95% CI)

p-value

DEHP
0.096 (-0.195, 0.387)
0.52
-0.044 (-0.291, 0202)
0.72
e
DBP
0.081 (-0.194, 0.356)
0.56
0.076 (-0.154, 0.307)
0.51
f
DiBP
0.137 (-0.142, 0.416)
0.34
0.069 (-0.166, 0.304)
0.56
MEP
0.010 (-0.168, 0.189)
0.91
0.008 (-0.142, 0.157)
0.92
MBzP
-0.088 (-0.365, 0.190)
0.53
-0.150 (-0.382, 0.082)
0.20
MCPP
-0.048 (-0.359, 0.263)
0.76
-0.067 (-0.328, 0.194)
0.61
MCOP
0.172 (-0.089, 0.433)
0.20
0.014 (-0.209, 0.237)
0.90
g
MCNP
0.369 (0.081, 0.658)
0.01
0.181 (-0.068, 0.431)
0.15
a
phthalate metabolite concentrations and inflammation biomarker levels were logtransformed. coefficients shown are based on a 10-unit change on the natural scale
b
adjusted for age, creatinine, alcohol intake, socioeconomic status, and smoking status
c

adjusted for model 1 + BMI
sum of MEHP, MEHHP, MEOHP, and MECPP
e
sum of MBP and MHBP
f
sum of MiBP and MHiBP
d

g

p<0.05
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Table 7. Multiple linear regression and 95% confidence intervals for phthalate metabolite
concentrations and CRP levels (n=258) among participants not currently using NSAIDsa
Model 1b
Beta (95% CI)

p-value

d

Model 2c
Beta (95% CI)

p-value

DEHP
0.376 (0.005, 0.747)
0.047g
0.236 (-0.058, 0.530)
0.12
e
DBP
-0.033 (-0.372, 0.306)
0.85
-0.050 (-0.317, 0.216)
0.71
f
DiBP
0.034 (-0.298, 0.367)
0.84
0.045 (-0.217, 0.307)
0.74
MEP
0.092 (-0.168, 0.352)
0.49
0.061 (-0.144, 0.266)
0.56
MBzP
0.282 (-0.065, 0.629)
0.11
0.10 (-0.176, 0.376)
0.48
MCPP
0.263 (-0.111, 0.637)
0.17
0.181 (-0.114, 0.476)
0.23
g
MCOP
0.553 (0.171, 0.934)
0.0005
0.382 (0.079, 0.685)
0.01g
MCNP
0.584 (0.210, 0.957)
0.002g
0.345 (0.046, 0.644)
0.02g
a
phthalate metabolite concentrations and inflammation biomarker levels were logtransformed. coefficients shown are based on a 10-unit change on the natural scale
b
adjusted for age, creatinine, alcohol intake, socioeconomic status, and smoking status
c

adjusted for model 1 + BMI
d
sum of MEHP, MEHHP, MEOHP, and MECPP
e
sum of MBP and MHBP
f
sum of MiBP and MHiBP
g
p<0.05

24

Table 8. Multiple linear regression and 95% confidence intervals for phthalate metabolite
concentrations and IL-6 levels (n=105) among participants not currently using NSAIDsa
Model 1b
Beta (95% CI)

p-value

Model 2c
Beta (95% CI)

p-value

DEHPd
0.084 (-0.261, 0.429)
0.63
-0.069 (-0.363, 0.225)
0.64
e
DBP
-0.090 (-0.447, 0.267)
0.62
0.009 (-0.294, 0.312)
0.95
f
DiBP
0.224 (-0.145, 0.593)
0.23
0.130 (-0.183, 0.443)
0.41
MEP
0.096 (-0.152, 0.344)
0.44
0.122 (-0.086, 0.330)
0.25
MBzP
0.050 (-0.321, 0.421)
0.79
-0.048 (-0.362, 0.265)
0.76
MCPP
-0.075 (-0.465, 0.315)
0.70
-0.045 (-0.373, 0.283)
0.78
MCOP
0.223 (-0.125, 0.570)
0.21
0.006 (-0.297, 0.309)
0.97
MCNP
0.401 (0.017, 0.784)
0.04g
0.193 (-0.142, 0.527)
0.26
a
phthalate metabolite concentrations and inflammation biomarker levels were logtransformed. coefficients shown are based on a 10-unit change on the natural scale
b
adjusted for age, creatinine, alcohol intake, socioeconomic status, and smoking status
c

adjusted for model 1 + BMI
d
sum of MEHP, MEHHP, MEOHP, and MECPP
e
sum of MBP and MHBP
f
sum of MiBP and MHiBP
g
p<0.05
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